ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
October 10, 2017 08:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA - 10...
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
September 11, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Phase 1 clinical trial results in...
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
September 06, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
August 30, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA - 30...
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
August 15, 2017 16:05 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Patient Enrollment Progressing for...
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
August 07, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA - 07...
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
June 29, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Phase 2 nolasiban previously reported...
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
June 07, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- OBE2109 is a GnRH receptor antagonist...
ObsEva SA to Attend Jefferies Healthcare Conference in NYC
May 31, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA - 31...
ObsEva Reports First Quarter 2017 Financial Results and Business Update
May 18, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Phase 3 Programs Underway in Uterine...